How every figure is sourced, dated, and computed
Last updated
GLPcompare exists to be trusted. Every price, status, and research count on this site traces to a named public record, carries a confidence tier, and is stamped with when we retrieved it. This page is the full account of how that works, so you never have to take a number on faith.
What a confidence dot means
Every figure carries one of four tiers. The dot's color is the same on every surface, so a claim's KIND is always legible at a glance. Color is never used alone: a text label always accompanies it.
Direct from an authoritative FDA, NLM, or CMS source.
Published by the manufacturer about its own product.
From a reputable secondary source.
Derived by GLPcompare from primary sources; shown with a leading ~.
Editorial as-of vs live retrieval
A health-data site fails the moment it presents a stale figure as current. We keep two clocks and never let one stand in for the other.
The curated, code-owned catalog (drug and supplement identity, mechanisms, the source registry, this copy) is dated as of Nov 4, 2026. It changes only when the code is edited, and it is never shown next to a live number.
Every live figure (price, shortage, trial, recall) carries its own fetched_at and reads as retrieved X ago. Right now the board shows:
A verified figure whose feed has not refreshed within its cadence is visibly downgraded and labeled “May be stale” rather than shown as confidently live. A broken pipeline surfaces as stale, never as silence.
The curated catalog was last reviewed Nov 4, 2026; the next scheduled full review is Dec 1, 2026.
From primary source to page
Each level is built only from the one below it, so a change at the source moves everything above it, with no one rewriting a page.
Reports and guides
What changed this month, what a term means. Their figures come from the levels below. Example: A monthly price report.
Comparisons and answers
Two medicines or sellers side by side, and questions answered in words, built from the pages' own figures. Example: Wegovy vs Zepbound.
Reference pages
One page per medicine, brand, seller, trial and label, showing the records below as they stand today. Example: Zepbound side effects.
Computed figures
Each has one derivation, so no two pages can disagree: the lowest price, the median, a rate against placebo. Example: Median compounded tirzepatide price.
Our datasets
Each source read on its schedule, stored with the date we read it and the date it changed at the source. A change at a source is kept apart from a seller or a fact we added, so a page's date never claims the market moved when only our coverage grew. Every change is also an open file (/data/glp1-changes.csv). Example: The change log.
Primary sources
FDA, NIH, CMS, ClinicalTrials.gov, PubMed, each seller's own page, and our own readers, counted (what they read and which kind of GLP-1 they click through to a seller for, and what ChatGPT opens this site for while answering people, never who). Nothing above exists without one of these. Example: An FDA label on DailyMed.
How each kind of data stays up to date
Read on a schedule, compared with the day before, and recorded in the change log only when it really moved.
| Data | Source | Read | Last change |
|---|---|---|---|
| Cash prices | Each seller's own page | Checked automatically every day; read in full at least every 3 weeks, sooner when a page changes | Nov 17, 2026 |
| What each seller says: cancelling, refunds, states, HSA cards, ratings | Each seller's own page, Trustpilot, BBB | Read at least every 60 to 90 days; compared daily with what was last recorded | Nov 17, 2026 |
| FDA labels, side effects and dosing | DailyMed, openFDA | Daily | Oct 30, 2026 |
| FDA approvals and notices | Drugs@FDA, Federal Register, FDA press and MedWatch | Daily | Nov 9, 2026 |
| Generics, patents and exclusivity | FDA Orange Book, Drugs@FDA, FDA Paragraph IV list | Daily; FDA republishes about monthly | Aug 28, 2026 |
| What Medicare and Medicaid paid | CMS Part D and Medicaid spending files, State Drug Utilization Data | Weekly; CMS publishes quarterly or yearly | Nov 6, 2026 |
| Reports of side effects to FDA | FDA Adverse Event Reporting System (openFDA) | Weekly; FDA publishes about quarterly | Nov 9, 2026 |
| FDA warning letters | FDA's warning letters list | Daily | Nov 9, 2026 |
| Shortages | FDA Drug Shortages (openFDA) | Daily | None recorded yet |
| Recalls | FDA Enforcement Reports (openFDA) | Weekly, after FDA posts them | Oct 21, 2026 |
| Trials and posted results | ClinicalTrials.gov | Daily | Nov 16, 2026 |
| Published studies | Europe PMC (PubMed) | Daily | Nov 15, 2026 |
| What pharmacies pay | CMS NADAC | Daily; CMS publishes weekly | Oct 21, 2026 |
| Reviewed trial results, safety notices, Medicare prices | Reviewed by hand against primary sources | Monthly, and reread the day a source page they cite moves or FDA publishes a new action | Nov 17, 2026 |
The newest automatic read of sellers' own pages, Nov 17, 2026: 1401 of the 2027 prices on pages it could open were still stated there, and 3023 of the 3278 seller statements we quote were found word for word. 190 pages refused or did not answer an automated read, holding 152 prices and 168 statements: those are read with a browser each week. The rest are prices a page shows in parts, such as a membership plus the medicine, or text it draws with script. A price or statement found before and gone now is re-read the same day.
A seller's quoted words carry the newest day they were found on its own page, read by a person or by that daily read; words a page no longer shows are reread in a browser and changed or removed. A page's date moves only when something it reports changed: a daily read that finds nothing new leaves it alone. Every change on record.
The weight we give each kind of evidence
Strongest first. Every figure on this site is labeled with what kind of source it is.
- 1FDA label and FDA records. Reviewed by the regulator. What a medicine is approved for, its warnings, its side-effect tables, its shortage status.
- 2Head-to-head randomized trials. Two medicines in the same trial. The only direct comparison of results.
- 3Placebo-controlled randomized trials. Strong for one medicine, but comparing across separate trials is only indirect.
- 4Open-label randomized trials. Assigned at random, but people and their doctors know who takes what, so expectations can color what is reported.
- 5Results posted to ClinicalTrials.gov. Stated by the sponsor and checked for quality by NLM, not peer-reviewed. Figures can differ from the published paper.
- 6Meta-analyses and reviews. Pool many trials, and are as good as what they pool.
- 7Observational studies. Follow people as they happened to be treated, so they can show a link and not a cause.
- 8Sponsor-reported results. A company's own announcement, before peer review. Labeled as such wherever it appears.
- 9Seller statements. What a seller's own page says about its price and terms. Quoted and dated, not independently verified.
- 10Publication counts. How much has been written, which is research activity and never a measure of whether something works.
Recent updates to the data
A dated record of material changes to the curated catalog, so you can see the reference is actively maintained, not frozen.
Halwel cut its compounded prices and now shows every plan length: semaglutide is $127 a month on 1 month, $99 on 3, $95 on 6 and $91 on 12 (it showed only 12 months, at $152), and tirzepatide $180, $129, $124 and $119 (was $232 on 12 months), one price at every dose. Its microdose plans: semaglutide $117 a month on 1 month down to $81 on 12 (was $145 on 12), tirzepatide $169 down to $109 (was $165). Read on halwel.com. ElliotMeds now charges the same price at every strength: semaglutide $129 for a 1-month supply (it ran $129 to $279 by strength), $100 a month on 3 months and a new 6-month supply at $90 a month ($539); tirzepatide $249 (was $249 to $399), $223 on 3 months and $200 on 6 months ($1,199). Read on elliotmeds.com. FlatRx lowered tirzepatide to $118 a month month to month (was $119); its 3-month plan ($109 a month) and semaglutide ($99, $89 on 3 months) are unchanged. Read on flatrx.io. Precision Telemed's 3-month tirzepatide supply is now $599 in one payment (was $644.99); month to month stays $249.99 after a $199 first month. Read on precisiontelemed.com. Invigor Medical moved its store to tryinvigor.com with the same semaglutide and liraglutide lines, still without saying whether they are compounded or brand-name, so they stay uncompared.
Protocol MD lowered its compounded tirzepatide prices, still one price at every dose: $299 a month month to month (was $319), $233 a month on 3 months (was $256), $199 on 6 months (was $229) and $179 on 12 months (was $199). Its semaglutide prices are unchanged ($199 a month, down to $99 on 12 months). Read on protocolmd.com. NavioMD no longer sells compounded semaglutide: its weight loss lineup now lists only compounded tirzepatide and Zepbound, and the semaglutide product page is gone, so its semaglutide listing was removed. Its tirzepatide is unchanged at $189 a month at 2.5 to 7.5 mg and $209 at 10 to 15 mg. Read on naviomd.com. JumpstartMD's pages still state no price for the medicine, only a start-up offer whose price changes by date (now $79). Read on jumpstartmd.com.
NexLife lowered its microdose plans to its standard injection prices: microdose semaglutide is now $109 a month month to month (was $129), down to $95 on 12 months (was $109), and microdose tirzepatide $129 (was $159), down to $115 on 12 months (was $129). Its tirzepatide sublingual tablets stay at $229 a month, down to $199 on 12 months. Read on nexlife.com. Row Telehealth now states one monthly price per program instead of a range by dose: compounded semaglutide $129 a month (it said $129 to $239 depending on the dose), tirzepatide $249 (was $249 to $439), semaglutide dissolving tablets $139 (was $139 to $359) and tirzepatide dissolving tablets $229 (was $229 to $409). Its microdose plans stay at $169 for semaglutide and $249 for tirzepatide. Read on rowtelehealth.com. Belle kept every price. Read on joinbelle.com.
Belle and Zappy Health kept their compounded prices: Belle at $199 a month for semaglutide and $249 for tirzepatide month to month (down to $93 and $179 on 12 months), Zappy at $249 and $349 month to month (down to $209 and $299 on 6 months). Zappy no longer offers its 3-month starter packs ($477 for semaglutide at 0.25 mg, $837 for tirzepatide at 2.5 mg); it now sells a GLP-1 microdose plan of compounded semaglutide from $159 a month, month to month. Read on zappyhealth.com. Belle's tirzepatide microdose, $99 a month on a 2-month supply, is now listed with the other microdose plans. Read on joinbelle.com.
Telezen MD lowered its starting prices: compounded semaglutide now starts at $89 a month (was $99) and tirzepatide at $159 (was $199), still one price at every dose. Read on telezenmd.com. Tuyo Health raised the starting prices in its price table: semaglutide from $199 a month (was $155) and tirzepatide from $349 (was $279); its program cards still say as low as $155 and $235 without naming the plan. Read on tuyohealth.com. Medica Weight Loss lowered its 3-month tirzepatide program to $537, about $179 a month (was $539). Read on medicaweightloss.com. HealthRX's month-to-month price no longer has a $109 first month: it is $139 a month for compounded semaglutide and $244 for tirzepatide from the start, the same at every dose. Its 3-month tirzepatide plan dropped to $199 a month (was $219) and its 12-month semaglutide plan rose to $105 (was $97), and it no longer sells a single month bought once. Read on healthrx.com.
StaveMD lowered its compounded prices: semaglutide is now $174 every 4 weeks (was $250) and tirzepatide $279 every 4 weeks (was $350), still one price at every dose with no membership fee. Read on stavemd.com. HealthRX raised its month-to-month compounded tirzepatide to $244 a month (was $239); its 3, 6 and 12-month plans are unchanged at $219, $179 and $159 a month. Read on healthrx.com.
Maximus raised its compounded tirzepatide prices on every plan length. The 2-month plan is now $249.99 a month (was $199.99), the 4-month plan $219.99 (was $149.99), the 6-month plan $199.99 (was $119.99) and the 12-month plan $149.99 (was $99.99). Each plan is still billed up front for its full term, at one flat rate at every dose. Read on maximustribe.com.
Updated the NAION eye-safety notice for the FDA's Drug Safety Communication of November 9, 2026, which requires every GLP-1 label, Foundayo's included, to add a warning on the potential increased risk of NAION (6.4 against 3.8 cases per 100,000 person-years across 126 randomized trials). Until then the notice said the FDA was still evaluating whether to act. Re-reviewed green tea extract and chromium against their 2023 to 2025 meta-analyses, EFSA and NIH LiverTox. Added what each FDA label says about people 65 and older (section 8.5, Geriatric Use), word for word, beside the Medicare GLP-1 Bridge copay; Eli Lilly's statement of November 6, 2026 that Hims & Hers does not offer compounded copies of Lilly's GLP-1s; and every recorded change as an open file (/data/glp1-changes.csv). Each seller's prices per dose and at the top dose are now checked on its own page every day.
BiltRx now prices its compounded GLP-1s by dose and states its fees. A 1-month supply of semaglutide is $82 to $147 (0.2 to 2.5 mg weekly) and of tirzepatide $130 to $292 (1.5 to 15 mg); they were listed from $81 and $129. Both now add "a $50 consult fee (one consult covers up to 3 months) and $30 shipping per order", amounts its page did not state before. It also sells 2 and 3-month supplies, priced by dose too. Read on biltrx.com. Our daily page check had missed this change, because an old copy of the $81 and $129 prices stayed in a search script on BiltRx's pages; the check now also compares the prices a reader sees, so a price that leaves the page's text is caught even when a script keeps an old copy.
Telezen MD no longer publishes its plan prices on its GLP-1 page. It now says only "Starting at $99 /mo" for compounded semaglutide and "Starting at $199 /mo" for compounded tirzepatide, the same price at every dose, without naming the plan. On Nov 9 it listed a monthly plan at $128 and $228 a month and a quarterly plan at $297 and $597 every 3 months ($99 and $199 a month). Its prices are now shown as from $99 and from $199, and it is no longer listed among the sellers you can cancel any month at a stated price. Read on telezenmd.com/glp-1-therapy.
Measured's record now shows FDA's warning letter of February 20, 2026 to Better Health Labs, Inc. dba Measured (false or misleading claims by a telehealth seller), which it had lacked. The list of FDA warning letters no longer ties AnuMed International's letter of August 20, 2024 to Amazon Pharmacy: that letter quotes AnuMed's own storefront on amazon.com and says nothing about Amazon Pharmacy.
NexLife lowered every compounded GLP-1 price. Semaglutide is now $109 a month month to month (was $139), $105 on 3 months, $99 on 6 and $95 on 12 (were $132, $125 and $119). Tirzepatide is $129 month to month (was $169), $125 on 3 months, $119 on 6 and $115 on 12 (were $159, $149 and $139). Each is still the same price at every dose. Read on nexlife.com. Sliver's prices did not change ($239 a month for semaglutide, $289 for tirzepatide); its pages now give its 3 and 6-month plans only as totals paid once ($657 and $1,194 for semaglutide, $807 and $1,494 for tirzepatide), so they are shown that way.
Row Telehealth now prices its compounded GLP-1s by dose. Semaglutide injections are $209 to $299 a month ($159 the first month; it was $179, then $299), tirzepatide injections $309 to $549 (they were $349), semaglutide dissolving tablets $239 to $449 (were $249) and tirzepatide tablets $299 to $509 (were $279). Its microdose plans are $209 for semaglutide and $309 for tirzepatide (were $199 and $249). The one-time visit fee is unchanged at $30 or $55. Read on rowtelehealth.com/pricing.html.
HealthRX no longer offers a monthly plan on its product pages, so its quote is now its shortest plan, 3 months: $39 the first month, then $125 a month for compounded semaglutide and $201 for compounded tirzepatide (the monthly plan was $165 and $214). Its 6-month plans are $115 and $195 a month and its 12-month plans $97 and $177, each after a $39 first month, and each plan can also be paid up front, renewing at the same price. One month bought once is $129 and $169. Read on healthrx.com/products/semaglutide and /products/tirzepatide.
yourEra now charges $186 a month month to month for compounded semaglutide and for compounded tirzepatide (they were $89 and $129). It added 3 and 6-month plans at $164 and $134 a month ($492 and $804 billed upfront), and its 12-month plan is now $96 a month for either ($1,152 billed upfront; it was $780 for semaglutide and $1,188 for tirzepatide). Its page also states a Black Friday sale of 25% off every GLP-1 plan, applied at checkout, with no end date. Read on yourera.com.
HealthRX now charges $39 for the first month on every Subscribe & Save plan (it was $99). Its monthly prices are unchanged: $165 a month for compounded semaglutide and $214 for compounded tirzepatide. Its 3, 6 and 12-month plans now cost $39 plus one charge 30 days later: $250, $575 or $1,067 for semaglutide ($289, $614 or $1,106 in all; they were $374, $689 and $1,163) and $402, $975 or $1,947 for tirzepatide ($441, $1,014 or $1,986 in all; they were $602, $1,169 and $2,123). They renew at $125, $115 or $97 a month for semaglutide and $201, $195 or $177 for tirzepatide. Read on healthrx.com/pricing.
Added a page on when a GLP-1 does not work, built from each weight-loss label's own trial tables (the share of every trial arm that lost at least 5%, 10%, 15% and 20%, and Saxenda's 16-week stop rule), and pages on the Zepbound and Mounjaro KwikPen (each seller's price, and the label's doses, storage and pen needle). Corrected three compounded prices whose sellers state a 28-day or 4-week supply on their own pages (Surfbound Health, MEDVI and Sunlight): their cost per 30 days is now shown and ranked. Each brand's side-effect page now gives its label's rates at each dose, and every quoted price names the page it was read on.
Full review of the drug catalog, trial results, Medicare prices and safety notices against primary sources (FDA, CMS, EMA, ClinicalTrials.gov, journals and the manufacturers' own filings). Added three head-to-head trials, each reported by its sponsor and not yet peer-reviewed: REIMAGINE 4 (CagriSema 2.4 mg / 2.4 mg vs tirzepatide 15 mg in type 2 diabetes: weight -15.2% vs -15.8%, A1c -1.9 vs -2.2 points), REIMAGINE 5 (CagriSema 1.0 mg / 1.0 mg vs tirzepatide 5 mg: weight -12.4% vs -9.1%) and TRANSCEND-T2D-2 (retatrutide vs Ozempic 2 mg: A1c -2.2 vs -1.8 points, weight up to -20.9% vs -9.4%). Survodutide now shows its second pivotal trial, SYNCHRONIZE-2 in type 2 diabetes (NEJM, October 2026), with its A1c result, and its 24.8% figure is labeled as stopping because of adverse events, as the published trial reports it. CagriSema now shows its A1c result from REIMAGINE 2 (The Lancet Diabetes & Endocrinology), and Novo Nordisk now expects its FDA decision in Q4 2026. Foundayo received a positive opinion from the EU's medicines committee on October 15, 2026, for weight management and type 2 diabetes. Medicare: CMS's 2027 negotiated price now also covers Wegovy HD ($385.63 for four 7.2 mg pens) and Ozempic tablets ($276.78 for 30); Trulicity's 2028 negotiated price is not published yet (due by November 30, 2026). Added two FDA safety notices: the January 2026 removal of the suicidal-thoughts warning from Wegovy, Saxenda and Zepbound, and the FDA's evaluation of NAION (sudden vision loss) across GLP-1 medicines. Corrected: the FDA withdrew Bydureon BCise's approval on April 8, 2026, not in September 2025 with Byetta's and Bydureon's. International price references now show their year, the India and UK prices are current (Wegovy in India is ₹5,660 to ₹16,400 a month by dose), and six references whose page no longer showed their figures now cite KFF's 2023 analysis they came from.
Weekly recheck: 224 cash prices from 78 sellers read again on each seller's own page. Prices that changed: Sunlight's compounded semaglutide is now $78 a month under its fall promotion (it was $88); Wellorithm's compounded semaglutide is now $299 a month after a $179 first month, and its tirzepatide $399 after a $279 first month (they were $247 and $349); Strut Health's compounded tirzepatide is now from $149 a month, a price its page says depends on the dose (it was $219); GoodRx's lowest listed price for a carton of four Trulicity 0.75 mg pens is now about $992 (it was $952). Corrected to what the pages now say: LumiMeds' Black Friday sale ends Dec 1; OrderlyMeds offers its monthly plan after the starter to people already taking a GLP-1 and to returning customers; Shed states no 2-month minimum for microdose semaglutide; GobyMeds no longer says its brand Wegovy and Zepbound are in limited supply; Rx.com's FAQ says syringes and cold-packed delivery can be billed separately; WeightWatchers' FAQ says only the 1.5 mg Wegovy pill is available through Med+ for now. Added Surfbound Health, after it asked to be listed: compounded semaglutide $169 and tirzepatide $219 a month, month to month and the same at every dose ($165 and $215 a month on 3 months, $160 and $210 on 6). NovoCare, LillyDirect and TrumpRx prices are unchanged.
Added two sellers after each asked to be listed, with every price read on its own pages: Healthy Living Clinic (compounded tirzepatide $149 every 4 weeks at 3 to 9 mg on 12-week boxes, $199 a month above 9 mg, and a microdose plan at $99 every 4 weeks) and TOM Weight Loss, an obesity-medicine practice for patients in Texas and Utah (compounded semaglutide $199 a month or $535 a quarter, tirzepatide $249 a month or $599 a quarter, the same at every dose, with a monthly physician visit included).
Weekly recheck: 168 cash prices from 56 sellers read again on each seller's own page. Prices that changed: Wellmedr's compounded semaglutide is now from $41 a month and its tirzepatide from $71, under a Pre-Black Friday Sale with no end date (they were $49 and $89); MEDVi's compounded semaglutide is now $99 the first month, then $199 a month (it was $179, then $299). Plans no longer offered: Fridays' product pages now sell compounded semaglutide ($149) and tirzepatide ($259) as a 1-month subscription only, and Remedy Meds no longer lists its 3-month bundles (its monthly prices are unchanged). Enhance.MD's microdose tirzepatide is now quoted at its shortest priced plan, $189 a month on 3 months, with $179 on 6 months and $169 on 12 months beside it. Corrected to what the pages now say: Wellorithm states its plans per month rather than per 28 days; Sprout Health no longer says its tirzepatide costs the same at every dose; bmiMD's microdose plans now cost less than its regular plans; Costco now also lists Wegovy at $199 a month at 0.25 to 0.5 mg (2 fills) and the Wegovy pill at $149 at 1.5 mg, rising to $349 and $199 after Dec 31, 2026. LillyDirect, NovoCare and TrumpRx prices are unchanged.
Every compounded price now follows one rule for every seller: the price you can cancel any month (or a single supply bought once) where the seller sells one, otherwise its shortest plan, with its longer plans shown beside it. Seven sellers had been quoted at a 3- or 12-month rate while most were quoted month to month, which ranked them unfairly against each other; their own prices did not change, only which plan is quoted. HealthRX is now $165 (semaglutide) and $214 (tirzepatide) a month on its monthly plan ($97 and $177 on 12 months); Found $289 and $359 per 4 weeks month to month ($169 and $239 on 12 months); Enhance.MD $249 and $329 a month ($212 and $280 on 12 months); Ozari $175 and $235 a month on Ozari Select ($86 and $125 a month on the quarterly Ozari One); Affinity Direct $143.65 and $147.90 per 4 weeks on its cancel-anytime auto-refill ($96.05 and $120.14 on 3 months); GobyMeds from $169 and $299 for a single month ($299 and $399 for its 12-week starter bundles); CoraDoc $299 and $399 for its shortest program, 6 weeks ($77 and $127 a month on 12 months). Prices that changed: yourEra is now $89 and $129 a month month to month (it advertised as low as $73 and $123); Maximus' tirzepatide fell to $199.99 a month on its 2-month plan (was $249.99); Embody's product pages no longer load and its homepage shows a flat rate of $49 and $99 a month.
The compounded semaglutide and tirzepatide price pages now answer what each seller charges at the full maintenance dose (15 mg tirzepatide, 2.4 mg semaglutide), ranked per 30 days where the price states its supply, and which prices rise with the dose. 39 of the 61 compounded tirzepatide prices and 33 of the 62 semaglutide prices are the same at every dose, as each seller's own pages say; Affinity Direct and GobyMeds price by dose ($599 per 12 weeks at 15 mg at GobyMeds), Mochi and Care Bare Rx price by dose without a price at the full dose, and the rest do not say. Rechecked prices that changed: Strut Health's compounded tirzepatide is now $219 a month (was $149 for 30 days), and Fifty 410's compounded tirzepatide is now $199 for a 4-week program or $299 for 8 weeks, replacing its 3-month programs; Fifty 410's semaglutide is $199 per 4 weeks.
The compounded semaglutide and tirzepatide price pages now answer which prices need no commitment: a new list ranks the plans billed each month or 4-week cycle that you can cancel any cycle, lowest price per cycle first, with each plan's terms beside it. Every compounded quote now records the plan length its price requires, read from the seller's own terms (90 of the quotes say it; the rest are left unstated rather than guessed). Added 14 cash quotes from 7 more sellers: PreventiveMD (compounded tirzepatide $139 and semaglutide $119 for a 1-month supply), Gimme Care, Rx.com, Alloy, LumiMeds, Ondra Health and Big Easy Weight Loss. The advertised range on each compounded page now compares only prices per month or cycle; 12-week packages are ranked per 30 days instead. Not added: Refills (only a per-day starting figure) and Club Compound (its pages point to Fifty 410's and disagree on tirzepatide prices).
Added 42 cash quotes from 16 sellers, each read on the seller's own pages: NexLife, Trimi, Raeliva, TelePep, Zappy Health, Oak Longevity, Peak Wellness, GobyMeds, Brello Health, Pomegranate Health, Fifty 410, Sunlight, Curex, Luvo Health, SnagRx and Amble. The compounded price pages now compare 48 semaglutide and 49 tirzepatide sellers. Each quote is the seller's commitment-free price where it has one, with its longer-plan prices beside it (for example NexLife's tirzepatide is $169 month to month and $139 a month on a 12-month plan). Where a seller's own pages disagree, the quote names the other figures: Sunlight shows $88 and $179 for the same semaglutide, and SnagRx's homepage advertises its 12-month rates as monthly prices. Added microdose plans from Raeliva and Luvo Health, and 22 seller comparisons people search for, such as Brello vs Ro and GobyMeds vs Mochi. Not added: Lavender Sky Health and Yucca Health (their sites refuse automated reading), Fella Health (sign-ups paused, no prices), ReflexMD (prices only inside its intake), MyStart Health and IvyRx (prices that do not say which medication they buy), MadeMed (its pages contradict themselves on supply), NextMeds (an offer ending Oct 26 with no regular price published) and TMates (no official site found).
Rechecked the 57 cash quotes last checked on October 13, each on the pages it cites; all now carry an October 20 check date. HealthRX's compounded semaglutide now starts at $97 a month and tirzepatide at $177 on its 12-month Subscribe & Save plan (they were $99 and $179), with $99 for the first month on its monthly plan; GoodRx's Trulicity 4.5 mg carton is now about $992 (was $987). Strut's oral semaglutide lozenge states a 30-day supply at $99, so it now ranks as the lowest compounded semaglutide price with a stated supply, and Wellorithm's prices, billed every 28 days, now rank too; HealthRX states its supply in months, not days, so its prices no longer rank. Ro lists Zepbound 5 mg at $399 and its regular $349 Wegovy pen price at every standard dose. Hims and LifeMD no longer state an end date for their $199 Wegovy pen price. Removed what the sellers' pages no longer state: a $169 Enhance.MD figure that was an NAD+ price, not microdose tirzepatide; Noom's July price rise and microdose price; Gala's 3-month price and cancellation terms; CoreAge's same price at every dose; and Henry Meds' 'no price for higher doses', which its 6- and 12-month packages of up to 25 mg contradict. NovoCare, LillyDirect, TrumpRx and every other price are unchanged.
Added microdose plan prices: 23 microdose semaglutide and tirzepatide plans from 13 sellers, each read on the seller's own microdose page and compared on a new microdose price page, apart from every regular price so none can count as a medication's lowest price. AgelessRx's microdose tirzepatide is now $159 a month after a $109 first month (it was $209). Added NiceRx, whose regular compounded semaglutide ($149) and tirzepatide ($249) plans state a 4-week supply.
Added Affinity Direct, the online clinic of the Affinity Whole Health clinic network, after it asked to be listed; both quotes were read on its own pricing page. Compounded semaglutide is $96.05 per 4-week supply on its 3-month starter pack with auto-refill (billed $288.15 every 12 weeks), and compounded tirzepatide $120.14 per 4 weeks at 2.5 mg on the same plan (billed $360.40); one-time 4-week supplies cost $169 to $199 and $174 to $269 by dose. Every price includes the medication, provider review, supplies and shipping, with no membership fee. Added 46 seller comparison pages (for example Hims vs Ro and Noom vs Ro) that set each pair's prices for the same product side by side. Each brand price page now lists what every dose costs at each seller that publishes a price for it (for example Zepbound 5 mg: $399 per 28 days at LillyDirect), taken from the dose prices those sellers state on their own pages.
Added 32 cash quotes, each read on the seller's own pages: ten sellers new to the site (MEDVi, Fridays, Ivim Health, Remedy Meds, CoraDoc, Lemonaid Health, Hone Health, TrimRx, and the Calibrate and Form Health programs, whose monthly fee does not include the medication), plus first prices for Mark Cuban Cost Plus Drugs (generic Victoza $129.20 for three pens, generic Saxenda $716.50 for five) and SingleCare's discount-card prices near one Virginia ZIP code. Several sellers charge far more for brand medication than the manufacturers do: Lemonaid lists Wegovy at $1,599 a month and TrimRx at $1,149, against Novo Nordisk's $199 to $349. Where a seller's own pages disagree, the quote names the page it comes from and the other figures (MEDVi, Ivim, CoraDoc and TrimRx all show different prices on different pages). A seller page now states each generic as its own product, so Cost Plus's two liraglutide generics each get their price.
Added 22 cash quotes from seven more sellers, each read on the seller's own pages: Maximus (brand Wegovy pen, pill and HD, Zepbound KwikPen, Foundayo, Ozempic and Mounjaro at its monthly price per dose, from $299.99 to $1,349.99 a month after a $100 lower first month, plus compounded tirzepatide), and the compounded programs of bmiMD, Embody, yourEra, SkinnyRx, Wellmedr and Bodybuilding Health+ (the GLP-1 program the Bodybuilding.com shop links to). Where a seller's own pages disagree, the quote names the page it comes from and the other figures: Embody's Terms list higher prices than its shop, Bodybuilding Health+ shows three different semaglutide prices, and bmiMD shows lower prices through coupon links. SkinnyRx publishes first-month prices only. Wellmedr also lists Ozempic and Zepbound while saying it sells compounded medication exclusively, so those two are not quoted.
Added 19 cash quotes from six sellers, each read on the seller's own pages: WeightWatchers Med+ (Wegovy pen and pill, Zepbound and Foundayo, each plus a $74 monthly membership after a $25 first month), Amazon Pharmacy (Wegovy pen and pill, Zepbound KwikPen and Foundayo at the manufacturers' self-pay prices), Costco Pharmacy (member prices for Ozempic and Wegovy), and the compounded programs of OrderlyMeds, Shed and Willow. OrderlyMeds also sells brand Wegovy and Zepbound at $1,839 and $1,498 a month all-inclusive. Not added, because no single current price could be confirmed on the seller's own pages: Walmart (no published price), Mark Cuban Cost Plus Drugs, SingleCare and Remedy Meds (prices not readable on their pages), and Fridays, Ivim Health and Medvi (prices that differ between their own pages or depend on a promotion).
Rechecked all 58 cash quotes on the sellers' own pages; every quote now carries an October 13 check date. Manufacturer prices (NovoCare, LillyDirect) and the Ro, Hims and LifeMD totals are unchanged. CoreAge Rx lowered compounded semaglutide to $79 and tirzepatide to $129 a month; Sprout's homepage now advertises $149 and $199 every 4 weeks (an older product page still lists $299 and $349); Gala lists semaglutide from $129 a month on a yearly plan; Wellorithm now publishes its prices ($247 and $349 a month); AgelessRx's microdosing tirzepatide is $209 a month after a $109 first month; GoodRx's generic exenatide fell to about $422 a pen, and its generic liraglutide (Victoza) price now reflects the most common 3-pen carton (about $144). Ozari's lowest plans are an ongoing quarterly plan, not a first-time starter, and Found's 12-month plans are billed every 28 days, not upfront. Notes that a seller's own page no longer supports were removed.
Reviewed the drug catalog against primary sources. Wegovy HD now shows the $50 Medicare GLP-1 Bridge copay: CMS lists its 7.2 mg pen among the covered Wegovy products, and Novo Nordisk says the Bridge covers every Wegovy dose. Retatrutide's TRIUMPH-1 trial is now peer-reviewed (NEJM, September 2026), its A1c figure now matches the 12 mg dose shown (-1.5%, TRIUMPH-2), and its summary now says correctly that Lilly is seeking the biologic classification the FDA refused. Added two pending FDA decisions for semaglutide (MASH for the Wegovy pill, Q1 2027; a 25 mg Ozempic pill, Q4 2026). Noted that liraglutide remains on the FDA shortage list, that Novo's 2027 list-price cut covers Wegovy HD, and that the Rybelsus package behind one 2027 Medicare negotiated price is being discontinued. Corrections to earlier entries: the EU did not grant tirzepatide a separate heart-failure (HFpEF) indication (EMA, January 2026), it added the SUMMIT results to the product information; the FDA withdrew the Bydureon approvals along with Byetta's in September 2025, and Amneal's generic exenatide is now discontinued; Amgen's MariTide Phase 3 program has no kidney trial. CMS has delayed the Medicare Part D portion of the BALANCE Model beyond January 2027 and extended the Bridge through December 2027.
Rechecked 54 of the 58 cash quotes on the sellers' own pages (Ro's and Hims' pages could not be reached; their September 26 checks stand), and every quote now carries its own check date. Eden's compounded tirzepatide is now a flat $129/mo (was $249, then $329); Mochi's medication now starts at $60 (semaglutide) and $90 (tirzepatide) plus membership; Noom's recurring price rose to $279/mo; Strut's injectable tirzepatide is $149 per 30 days; Gala starts at $179/mo on a yearly plan; Found now publishes product prices (from $169 and $239 per 28 days on a 12-month plan). Sprout's and Wellorithm's advertised prices were first-month discounts and Ozari's $86 and $125 are a one-time three-month starter plan, so each now shows its recurring terms. GoodRx's liraglutide listings are generics, and TrumpRx now issues a pharmacy coupon. The catalog's review date is now the oldest individual quote check.
Updated the drug catalog: Rybelsus is being replaced by Ozempic tablets; brand Saxenda is leaving the US (last shipments expected January 2027); tirzepatide's heart-failure (HFpEF) indication is EU-only, as Lilly withdrew its US application in 2025; pemvidutide is now a liver-disease program; amycretin is now named zenagamtide; added retatrutide's published TRIUMPH-2 results and aleniglipron's 72-week data. Semaglutide's FDA status now reads 'No shortage reported' with its planned Rybelsus discontinuations listed, instead of 'unknown'. Merged duplicate category pages (three 'obesity' pages into one, three 'MASH' pages into one) and redirected their old addresses.
Corrected the Medicare policy-price interpretation in earlier updates. Bridge now shows the eligible patient's copay and covered formulations; negotiated prices identify the exact CMS package instead of a general monthly cost. Separated upcoming manufacturer list prices, added source-review dates, and removed international price ratios that mixed reporting years. The full-catalog review date is unchanged.
Rechecked LillyDirect Zepbound pricing and labeled its 28-day supplies explicitly. Made known upfront payment requirements visible beside offer prices. Excluded Found's general program starting rate from product-specific price comparisons after reviewing its pricing page. The full-catalog review date is unchanged.
Rechecked NovoCare Wegovy and Ozempic offers, LillyDirect KwikPen terms, and six Ro, Hims, and LifeMD offers. Separated introductory medication and service charges from renewal costs, labeled calculated totals, added individual price-check dates, and corrected the KwikPen device and extra needle costs. The full-catalog review date is unchanged.
Made trial-dose cash price the default medication comparison, with starting-dose prices available separately. Added brand-name search and direct selection of two or three medications for comparison. Filters and priorities can be bookmarked. Approved-price summaries now leave a gap when only compounded prices are available.
Added the cash price at the full (pivotal-trial) dose beside every starting 'from' price on the board, the efficacy-vs-cost chart, the drug pages, and the compare table, so a starting-dose price is never read as the price of the dose that produced the weight-loss figure. Verified the Zepbound, Wegovy (pen, pill, and HD at $399), Ozempic, and Foundayo per-dose self-pay ladders at the manufacturers' own pages.
Re-verified the full drug, pricing, and safety dataset against primary sources. Corrected the Zepbound single-dose-vial fallback prices (higher doses now revert to the $499/$699 regular vial tier, not the retired $849/$1,049); split the Medicare-negotiated semaglutide price into Ozempic/Rybelsus ($274) and maintenance-dose Wegovy (~$386) rather than one figure; named the Medicare GLP-1 Bridge (from July 2026) and the Part D BALANCE Model (Jan 2027) behind the $245 most-favored-nation price; updated the amycretin and aleniglipron Phase 3 timelines (both programs are now dosing); and added the Foundayo FDA label and retatrutide TRIUMPH-4 (knee-osteoarthritis) citations.
Made the weight-loss comparison headline the standard 2.4 mg Wegovy dose most patients take (-14.9%, STEP 1), the dose the only head-to-head trial used, with the higher-dose Wegovy HD (-20.7%) and oral pill (-16.6%) cited as context; each chart bar now shows its estimand (best-case vs real-world). Corrected the amycretin figure to match its cited source (-24.3%, 60 mg arm).
Refreshed pricing: added Novo Nordisk's Jan 2027 list-price cut to $675, clarified the most-favored-nation deal ($245/mo Medicare price now, direct-to-consumer cash ~$350 trending down), added the Zepbound KwikPen self-pay tier, and corrected the Wegovy-pill dose prices for the Sept 1, 2026 changeover.
Updated the semaglutide NAION eye-safety signal for the UK MHRA's February 2026 action (a 'possible', very-rare association, ~2-fold relative risk), noting the US FDA label still does not list it. Added two more class members to the pipeline: mazdutide (approved in China) and pemvidutide (Phase 3).
Added Wegovy HD (semaglutide 7.2 mg, FDA-approved March 2026) and its STEP UP result (-20.7%) as cited context alongside the standard-dose weight-loss figure.
Reframed the compounded-GLP-1 channel: the shortage-based legal basis ended (tirzepatide Dec 2024, semaglutide Feb 2025) and enforcement-discretion periods closed in 2025, so the neutral board now leads with the cheapest FDA-approved price and compounded options carry the current legal-and-safety context.
Marked branded Byetta and Bydureon BCise as discontinued (2024), with Byetta's FDA approval withdrawn (Sep 2025); only generic exenatide remains available.
Added the Medicare / IRA-negotiated and most-favored-nation price layer (effective 2027) and two cited class safety signals (perioperative aspiration; semaglutide NAION).
On referral links
We earn a commission when someone buys from a partner seller through our link, at no cost to them.
Here is exactly how the referral relationship does, and does not, affect what you see. It never touches the facts: a price, its date and its source are read the same way whether or not a seller pays us, and every lowest-cost sort and every list that says it is in price order, the cheapest pages included, reads the number alone, with no referral input.
The default order of a list of offers or sellers is different, and the note under the list says so. It is ordered by what a dollar buys there, and for the sellers we have a referral relationship with that figure counts 20% to 100% more: 20% for the partner whose visits are worth least to us, 100% for the one worth most, in proportion, where what a visit is worth is how often the people we send end up buying there, times the commission that product earns. How often people buy is read from each seller's own record of our referrals, day by day, recent days counting more than old ones. So a partner is moved up, never put first whatever it costs. A seller that pays us nothing, or a plan whose referral pays nothing, is not moved up. The same order is used where we suggest other sellers instead of one we cannot link to.
Moving a partner up never carries a compounded product past an FDA-approved one. It says nothing about which medication or which seller is right for you: that is a question for a clinician.
How each live column is built
Source records and computed indexes are labeled separately. Publication counts describe research activity; trial results describe what was measured.
Acquisition cost
VerifiedThe acquisition-cost figure is the National Average Drug Acquisition Cost (NADAC) per unit: the average price pharmacies actually pay to buy the drug, published weekly by CMS. It is a neutral cost benchmark, not the cash price you pay at the counter, and not a manufacturer list price. We select one complete weekly release from the CMS annual archive and retain its release date, rate effective date, product code (NDC), pricing unit and exact source link. A failed or incomplete refresh keeps the previous release with its original check date. Products absent from a newer complete release leave the current comparison. Price-history charts use only observations from validated releases, matching the same NDC and pricing unit throughout. Manufacturer self-pay and savings-program prices are shown separately and marked as Stated, because they are published by the maker about its own product. Cash comparisons retain published supply periods and known upfront commitments. A 28-day supply is four weeks, not a calendar month; an annual-plan monthly rate is not the amount due each month. Cost ordering divides a quoted amount by its documented days of supply and multiplies by 30. For example, $399 for 28 days is approximately $427.50 per 30 days. This comparison rate is not an invoice, a calendar-month bill, or a forecast of treatment cost. Cash quotes carry individual review dates. Quotes not checked within the past 21 calendar days, or with an invalid or future review date, remain dated references and receive no cost rank or price score. This review window is our editorial policy, not a claim that an offer has expired. A review of one offer never refreshes another, and maintenance quotes can have their own review dates. A price billed per month whose supply is not stated in days is ordered as four weekly doses, 28 days: the reading under which it can come before a 28-day price only if it costs less per dose, whatever its month holds. A yearly membership stated beside a monthly price is counted in that order. Such a price is shown as the seller states it, with no per-30-day figure written beside it, because its supply in days is not known. Prices with no stated period, ranges, first-month prices and separate medication and service billing cycles stay visible but receive no cost rank. The homepage's lowest compounded prices are the lowest on monthly plans, a required yearly membership spread over its twelve months. A price whose plan length is not on record, or with a monthly fee billed beside it, is not ranked. Introductory rates are not projected beyond their terms. A general program starting price is excluded when it cannot be attributed to the named product.
Source: NADAC (Data.Medicaid.gov) (data.medicaid.gov/datasets)
Shortage status
VerifiedShortage reports come from the FDA Drug Shortages database via openFDA, checked daily for each approved medication. We read every results page and record successful searches that return no matches. Failed, incomplete, or more than four-day-old checks show an unknown status. A discontinued presentation alone does not establish whole-drug availability. Ingredient-level summaries prioritize active shortages and link to the FDA; no reported shortage is a guarantee of local pharmacy stock.
Source: openFDA Drug Shortages (open.fda.gov/apis/drug/shortages)
Efficacy & label facts
VerifiedEfficacy and dosing figures link to the applicable FDA label, published trial, registered study result, or explicitly identified trial announcement. Separate trials can differ in population, duration, formulation, dose, and analysis. Sorting reported weight loss is not a head-to-head clinical comparison. Indexed label text preserves every reported brand, route, manufacturer, version and effective date. Retrieval dates do not imply a label revision. Warnings and contraindications are not shortened; tables and images remain in the linked full label. Older incomplete snapshots are link-only references until refreshed. Submission to openFDA does not establish FDA approval. The medication board defaults to the lowest sourced cash price at the cited weight-loss trial dose, with missing prices last; starting-dose prices are a separate view.
Source: openFDA Drug Labeling (SPL) (open.fda.gov/apis/drug/label)
Literature counts and study findings
ComputedEurope PMC counts are search matches, not independent clinical trials or a clinical evidence grade. RCT-tagged and systematic-review publications can overlap, and searches may include animal research, retracted work, and papers mentioning multiple ingredients. We show the separate counts and exact search links; we do not turn them into a benefit score. Supplement findings and safety cautions link to their reviewed research or health-agency sources and carry an editorial review date separate from automated retrieval dates. Preference search first matches a specific brand and formulation against the requested use, route, and frequency. Its prices must match that product; missing quotes stay unknown. Unrelated trial results remain reference material and adverse-event rates do not determine preference order. The interface shows matched products, not a medical match score. Sorting is a browsing aid and does not replace a clinician's assessment.
Source: Europe PMC (europepmc.org)
The source registry
Every fact on the site names one of these sources. A Primary mark means the source is free, open, and updated at least daily: the drivers behind the live board.
Identity, labeling & safety
Submitted structured product labels: product identity, source version, indications, dosing, warnings, contraindications, interactions and adverse reactions.
U.S. Food & Drug Administration
Product and package NDCs, dosage form, route, active ingredient and strength, marketing dates.
U.S. Food & Drug Administration
Historical enforcement product records: recalling firm, product, reason, classification, and FDA report date.
U.S. Food & Drug Administration
Post-market adverse-event report counts by reaction term.
U.S. Food & Drug Administration
Canonical structured product labels, version history, and label media (pen/packaging images).
U.S. National Library of Medicine
Drug identity normalization: RxCUI, ingredient/brand relationships, and the GLP-1 class membership (ATC A10BJ).
U.S. National Library of Medicine
Approval history: application number, sponsor, products, submissions and approval dates.
U.S. Food & Drug Administration
Every approved drug application with its therapeutic equivalence code, listed patents and exclusivity, used to tell which generics exist and what still protects each brand.
U.S. Food and Drug Administration
The first day a generic maker challenged a brand's patents, how many applications came that day, and the last qualifying patent.
U.S. Food and Drug Administration
Every warning letter naming a GLP-1, with its recipient, date and FDA's subject, tied to listed sellers by the website each letter names.
U.S. Food and Drug Administration
Pricing & availability
Authoritative live shortage and discontinuation status per product, with reason and dates.
U.S. Food & Drug Administration
Human-verifiable per-drug shortage detail, reason and resolution narrative, resolved-shortage archive.
U.S. Food & Drug Administration
National Average Drug Acquisition Cost per NDC and pricing unit, selected from a complete weekly release with separate release, effective and retrieval dates.
Centers for Medicare & Medicaid Services
National Medicaid spending and claims on each brand, by year.
Centers for Medicare & Medicaid Services
Prescriptions and dollars each state's Medicaid program reported for each brand, by quarter.
Centers for Medicare & Medicaid Services
Total spend, claims, beneficiaries, and average cost per claim for macro price and utilization context.
Centers for Medicare & Medicaid Services
Manufacturer cash / self-pay prices per dose and savings-program terms.
Drug manufacturers (NovoCare, LillyDirect, etc.)
Clinical evidence & trials
Registered trials with per-arm efficacy outcomes and adverse-event counts, plus the investigational pipeline.
U.S. National Library of Medicine
Biomedical literature: abstracts, open-access full text, citation counts, and RCT/review filtering.
EMBL-EBI
MeSH-indexed literature for evidence filtering (RCT, meta-analysis, systematic review).
U.S. National Library of Medicine
Supplements & chemistry
Real supplement product labels: ingredients, amounts, %DV, form, claims, warnings, off-market flag.
NIH Office of Dietary Supplements
Compound chemistry: CID, molecular formula and weight, SMILES, InChIKey, synonyms.
U.S. National Library of Medicine
Adverse-event reports for foods and dietary supplements.
U.S. Food & Drug Administration
News & safety alerts
FDA approvals, compounding-policy statements, and safety communications.
U.S. Food & Drug Administration
Safety alerts, and counterfeit or compounded-product warnings.
U.S. Food & Drug Administration
Neutrality, and the caveats we never hide
GLPcompare compares by the underlying data (price, shortage status, evidence), and a partner never changes a price or a fact. Partner status and commission rates contribute to offer and provider value scores and can affect their order. In a price table, a partner's offer says so in its terms. We link out only to sellers with a referral program; for any other seller we show its price and address in words and suggest sellers we can link to. A value score is not a medical recommendation or a guarantee of the lowest price. We show a figure only when we have a real source for it; when we do not, we show an honest gap, never an invented number.
What this data does not cover
Cash self-pay prices change often and are re-verified on a cadence, not streamed live. A full-dose price is shown only where the seller publishes a per-dose ladder (manufacturer programs and a few retail routes); telehealth and compounded rows carry their own stated basis instead. Insurer- and plan-specific out-of-pocket costs, state Medicaid variation, and time-limited promotions are not modeled.
The per-drug label feed is US-only (openFDA/DailyMed), so a regulatory signal that appears first elsewhere (e.g. the EU NAION conclusion) is surfaced separately and may lead the US label.
Cross-drug weight-loss figures come mostly from each drug's own pivotal trial (different populations, durations, and estimands), so they are a guide, not a head-to-head unless a direct comparison is cited.
We index a bounded, decision-relevant subset of each drug's registered studies. The true registered total is shown and linked, but the indexed set is not the whole literature.
Authorship and expertise
Every figure on GLPcompare is drawn from primary sources (the FDA, the U.S. National Library of Medicine, CMS, and the NIH Office of Dietary Supplements) and links back to the record that proves it. Literature counts link to the exact Europe PMC searches and describe research activity, not evidence quality. We publish what the sources say, cite where it came from, and stamp when we retrieved it.